advertisement
Journal of Ocular Pharmacology and Therapeutics 18
Showing records 1 to 18 | Display all abstracts in Journal of Ocular Pharmacology and Therapeutics106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Weinreb RN
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
105868 Magic Bullets: The Coming Age of Meaningful Pharmacological Control of the Corneal Responses to Injury and Disease
Wilson SE
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 594-606
106238 Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma
Sakata R
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 63-69
105906 Cytotoxic, Apoptotic, and Oxidative Effects of Preserved and Preservative-Free Brimonidine in a Corneal Epithelial Cell Line
Kucukoduk A
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 576-583
106238 Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma
Fujishiro T
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 63-69
105906 Cytotoxic, Apoptotic, and Oxidative Effects of Preserved and Preservative-Free Brimonidine in a Corneal Epithelial Cell Line
Durmus IM
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 576-583
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Bacharach J; Brubaker JW
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
105906 Cytotoxic, Apoptotic, and Oxidative Effects of Preserved and Preservative-Free Brimonidine in a Corneal Epithelial Cell Line
Aksoy M
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 576-583
106238 Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma
Saito H
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 63-69
105906 Cytotoxic, Apoptotic, and Oxidative Effects of Preserved and Preservative-Free Brimonidine in a Corneal Epithelial Cell Line
Karakurt S
Journal of Ocular Pharmacology and Therapeutics 2022; 38: 576-583
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Medeiros FA
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
106238 Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma
Nakamura N
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 63-69
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Bejanian M
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
106238 Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma
Honjo M
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 63-69
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Bernstein P
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
106238 Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma
Shirato S; Miyamoto E
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 63-69
106359 Bimatoprost Implant Biodegradation in the Phase 3, Randomized, 20-Month ARTEMIS Studies
Robinson MR
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 55-62
106238 Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma
Yamada Y; Aihara M
Journal of Ocular Pharmacology and Therapeutics 2023; 39: 63-69
